ANI PHARMACEUTICALS INC
ANI Pharmaceuticals reported Q2 2026 sales of $266.04M and net income of $24.71M, with year-on-year EPS growth. The company reaffirmed full-year 2026 net revenue guidance of $1.08B to $1.14B. The update supports its earnings outlook but investors face risks including pricing and payer pressure on Cortrophin Gel and generic competition.
ANI Pharmaceuticals reported Q2 2026 results. Adjusted diluted EPS was $2.21, above the $2.09 estimate, and revenue rose to $266.0M from $211.4M a year earlier. Adjusted net income was $47.6M. Cortrophin Gel revenue was $117.1M, up 43.5%. Full-year adjusted EPS guidance is $9.19 to $9.69.
ANI Pharmaceuticals reported record Q2 2026 net revenue of $266.0 million, up 25.9% year over year. GAAP net income was $24.7 million and adjusted EBITDA rose 32.4% to $71.6 million. Cortrophin Gel revenue grew 43.5% to $117.1 million, but full-year Cortrophin guidance was cut to $520–$540 million. ANIP shares fell 5.53% to $78.06.
Over the past 7 days, alphai's AI scored 9 news stories mentioning ANIP (ANI PHARMACEUTICALS INC). Coverage has skewed bullish: 6 bullish, 3 neutral, and 0 bearish.
In the last 30 days, ANIP insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($273K). The most active reporter was Cook Meredith, SR. VP, GENERAL COUNSEL & SEC., with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Reaffirmed 2026 revenue guidance plus a step-up in Q2 profitability strengthens the near-term earnings outlook, but highlights ongoing risks around rare-disease pricing and generic erosion.
The earnings beat plus raised/confirmed FY adjusted EPS range supports near-term upside bias, assuming investors focus on specialty product momentum.
The quarter beat supports growth momentum, but the Cortrophin Gel guidance cut is a near-term risk to 2026 expectations.
The call frames a near-term guidance trim as first-half catch-up, while emphasizing accelerating gout field time and operating leverage into 2027.
Beat on Q2 sales and EPS was offset by slightly weaker full-year revenue guidance, driving a post-report selloff.
alphai scores every news story that mentions ANIP with an AI model for sentiment and relevance, and aggregates insider trades from ANI PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
ANI Pharmaceuticals reported Q2 2026 sales of $266.04M and net income of $24.71M, with year-on-year EPS growth. The company reaffirmed full-year 2026 net revenue guidance of $1.08B to $1.14B. The update supports its earnings outlook but investors face risks including pricing and payer pressure on Cortrophin Gel and generic competition.
6 min readANI Pharmaceuticals reported Q2 2026 results. Adjusted diluted EPS was $2.21, above the $2.09 estimate, and revenue rose to $266.0M from $211.4M a year earlier. Adjusted net income was $47.6M. Cortrophin Gel revenue was $117.1M, up 43.5%. Full-year adjusted EPS guidance is $9.19 to $9.69.
2 min readANI Pharmaceuticals reported record Q2 2026 net revenue of $266.0 million, up 25.9% year over year. GAAP net income was $24.7 million and adjusted EBITDA rose 32.4% to $71.6 million. Cortrophin Gel revenue grew 43.5% to $117.1 million, but full-year Cortrophin guidance was cut to $520–$540 million. ANIP shares fell 5.53% to $78.06.
3 min readANI Pharmaceuticals’ Q2 2026 earnings call covered Cortrophin Gel gout expansion and guidance. CEO Nikhil Alwani said sales force reps expanded to 180 by end-June, with over 95% generating multiple patient cases. Full-year Cortrophin guidance was trimmed to $520-$540 million, citing first-half performance and factors beyond case counts. Operating leverage investment is expected to drive improved margins in 2027.
4 min readANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 revenue of $266 million, up 25.9% year on year, topping estimates by 2.4%. Non-GAAP EPS was $2.21, 8.2% above consensus. Full-year revenue guidance was $1.11 billion at the midpoint, about 1% below estimates. Shares fell 7.4% to $76.53 after results.
3 min readANI Pharmaceuticals reported second-quarter 2026 net revenues of $266.04M, up from $211.37M, and diluted EPS of $1.05 versus $0.36. Net income rose to $24.71M from $8.55M. Growth was attributed to Rare Disease (Cortrophin Gel) and generics volume. The company also noted a shift in U.S. ophthalmology promotion from YUTIQ to ILUVIEN.
1 min readANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 anip-20260807xexx991.htm EX-99.1 Document Exhibit 99.1 ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results • Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year • Purified Cortrophin ® Gel net revenues of $117.1 million, an
6 min readANI Pharmaceuticals (Nasdaq: ANIP) reported Q2 2026 net revenues of $266.0 million, up 25.9% year over year. Cortrophin Gel net revenues rose to $117.1 million (+43.5%). GAAP net income available to common shareholders was $24.7 million, and adjusted non-GAAP diluted EPS was $2.21. The company raised Cortrophin Gel guidance to $520-$540 million and reaffirmed full-year 2026 net revenue $1,080-$1,140 million and adjusted EBITDA $285-$300 million.
6 min readANI Pharmaceuticals (NASDAQ: ANIP) is set to report Q2 earnings before the bell. Last quarter, it reported revenue of $237.5M, up 20.5% YoY, and beat analysts on EPS and full-year EPS guidance. For Q2, analysts expect revenue growth of 22.9% YoY. ANIP shares are down 5.8% over a month; average analyst price target is $110 vs $79.88.
3 min readANI Pharmaceuticals (NASDAQ:ANIP) reported positive topline Phase 4 data from its open-label SYNCHRONICITY study of the fluocinolone acetonide intravitreal implant in 108 patients with chronic non-infectious uveitis affecting the posterior segment. The company said both goals were met, with vision improving about 3.6 letters and posterior swelling decreasing significantly. About 29% had treatment-related side effects, mainly eye pressure increases and cataracts.
4 min read
